5326122026-04-012026-06-305326122026-04-012026-06-30in-capmkt:OtherExpenses1Member5326122026-04-012026-06-30in-capmkt:OtherExpenses2Member5326122026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares532612INDOCONOTLISTEDINE873D01024INDOCO REMEDIES LIMITEDMain BoardEquity2026-04-012027-03-312026-07-282026-07-15INRLakhsQuarterlyFirst quarterSingle segmentPHARMACEUTICALS2026-07-2810:45:002026-07-2811:45:00Not applicablefalsefalseThe Company does not have any debt securities and there are no defaults on loan taken by the Company for the quarter ended 30th June, 2026. Hence the said disclsoure is not applicable to the Company.2026-04-012026-06-30UnauditedStandalone408970000044700000413440000085990000039590000014870000090650000022750000028050000013566000004175600000-41200000973400000932200000105600000340000010900000008232000000000823200000-450000081870000018460000028.928.92008.928.921. The unaudited Standalone Results for the Quarter ended 30th June, 2026, have been reviewed by the Audit committee and approved by the Board of Directors of the Company at its meeting held on 28th July, 2026. The Statutory Auditors have expressed an Unmodified Audit opinion on these unaudited Standalone Financial Results. <br /> <br /> 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. <br /> <br /> 3. The company has only one primary reportable segment of activity, namely, Pharmaceuticals. <br /> <br /> 4. Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: <br /> <br /> (Rs. in Lakhs) <br /> Net Sales Qtr ended Qtr ended Qtr ended Year ended <br /> & Income 30-06-2026 31-03-2026 30-06-2025 31-03-2026 <br /> from Operations (Unaudited) (Audited) (Unaudited) (Audited) <br /> <br /> India 22,775 19,363 22,255 89,413 <br /> Outside India 18,037 23,543 16,306 73,941 <br /> -------------------------------------------------------------------------------------------------------------------------- <br /> Total : 40,812 42,906 38,561 1,63,354 <br /> ============================================================== <br /> <br /> 5. The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 30th June, 2026. <br /> <br /> 6. Figures for the quarter ended 31.3.2026 represents the difference between audited figures in respect of the full financial year and published figures for the period ended 31.12.2025 (limited reviewed) . <br /> <br /> 7. (*) The Company completed the slump sale of its Ophthalmic Business Division to Sunways (India) Private Limited. The gain on sale of Rs 9,734 Lakhs has been recognized as an Exceptional Item in the Statement of Profit or Loss. <br /> RESEARCH & DEVELOPMENT185400000OTHER EXPENSES1171200000ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT & LOSS-6000000-6000000-1500000-4500000